Related Experiment Videos
Angiogenesis inhibition by minocycline
1Department of Neurological Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Cancer Research
|January 15, 1991
Summary
Minocycline, an antibiotic, effectively inhibits tumor-induced angiogenesis (new blood vessel growth) in rabbit corneas. This finding suggests potential new therapeutic strategies targeting collagen breakdown for cancer treatment.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Inhibiting angiogenesis is a promising strategy for cancer therapy.
- Agents disrupting collagen synthesis have shown potential as angiogenesis inhibitors.
Purpose of the Study:
- To evaluate minocycline, a semisynthetic tetracycline antimicrobial, as a novel inhibitor of angiogenesis.
- To assess the efficacy of minocycline in preventing tumor-induced neovascularization in a rabbit cornea model.
Main Methods:
- Minocycline was formulated into controlled-release polymers.
- The polymers were implanted into rabbit corneas containing VX2 carcinoma.
- Neovascularization and tumor growth were monitored over 21 days.
Main Results:
- Minocycline significantly inhibited tumor-induced angiogenesis, comparable to heparin and cortisone.
- Minocycline reduced angiogenesis by factors of 4.5, 4.4, and 2.9 at 7, 14, and 21 days, respectively.
- Corneas treated with minocycline showed no large, invasive, exophytic tumors compared to controls.
Conclusions:
- Minocycline is a potent inhibitor of angiogenesis and tumor growth.
- The anticollagenase properties of minocycline may contribute to its anti-angiogenic effects.
- Investigating collagenolysis inhibitors may reveal new therapeutic strategies for angiogenesis-related diseases.